Prostate Cancer Clinical Trials

289 studies are recruiting for prostate cancer in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies, page 3

1. COMPASS Study for Metastatic Castration-resistant Prostate Cancer

   This study is a companion to the SYNERGY-201 clinical trial (NCT06228053), which investigates SX-682 and enzalutamide in individuals with prostate cancer. Individuals must be participating in SYNERGY-201 in order to participate in this study. The purpose of this companion study is to learn more abo…

   Stage

   Not phased

   Ages

   18 and older

   Site

   UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California

   Locations

   4 in total

   Run by

   Duke University

   See if you can join NCT07050433 on ClinicalTrials.gov

2. PRISM Study: Prostate Recurrence Detection Using Imaging With PSMA PET/MRI Post-high Intensity Focused Ultrasound

   The purpose of this study is to compare the sensitivity of PSMA PET/MRI and standard MRI in detecting focal therapy failure in the prostate one year after High-Intensity Focused Ultrasound (HIFU) treatment. Specifically, the study aims to evaluate whether PSMA PET/MRI offers a higher sensitivity th…

   Stage

   Not phased

   Ages

   40 to 95

   Site

   NYU Langone Health, New York, New York

   Run by

   NYU Langone Health

   See if you can join NCT07184970 on ClinicalTrials.gov

3. Transrectal Ultrasound Robot-Assisted Prostate Biopsy

   Prostate cancer (PCa) is the most common non-dermatologic malignancy in U.S. men. Transrectal ultrasound (TRUS)-guided prostate biopsy is a commonly used diagnostic procedure for men with an elevated serum prostate-specific antigen (PSA) level and/or abnormal digital rectal examination (DRE). It is…

   Stage

   Not phased

   Ages

   45 to 75

   Site

   Johns Hopkins Hospital, Baltimore, Maryland

   Run by

   Johns Hopkins University

   See if you can join NCT02871726 on ClinicalTrials.gov

4. Characterizing the Genomic Landscape of Prostate Cancer in Native American Populations (NAT-Geno)

   The purpose of this study is to analyze tumor tissue samples from patients of Native American identity with prostate cancer. By examining these samples, researchers hope to understand how different genes in your tumor can influence treatment decisions, how your cancer progresses and the outcome of …

   Stage

   Not phased

   Ages

   18 to 100

   Site

   OU Health Stephenson Cancer Center, Oklahoma City, Oklahoma

   Run by

   University of Oklahoma

   See if you can join NCT06960798 on ClinicalTrials.gov

5. Precision-Based Genomics in Prostate Cancer

   Background: Prostate cancer is the most common cancer and the second leading cause of death in males in the United States. Researchers want to find additional gene mutations that may increase a man s risk for prostate cancer and may affect how aggressive the disease is. Objective: To look at gene m…

   Stage

   Not phased

   Ages

   18 to 120

   Site

   University of California San Diego, La Jolla, California

   Locations

   11 in total

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT04706663 on ClinicalTrials.gov

6. A Pilot Presurgical Trial of REGN5678 (Anti-PSMA x CD28) in Patients With High-risk, Localized Prostate Cancer Followed by Radical Prostatectomy

   To learn about the safety and effects of a drug called REGN5678 when it is given to patients with high-risk prostate cancer.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   M D Anderson Cancer Center, Houston, Texas

   Run by

   M.D. Anderson Cancer Center

   See if you can join NCT06085664 on ClinicalTrials.gov

7. DESTINY-PANTUMOUR04

   This study will evaluate the effectiveness of T-DXd in patients with HER2-positive (IHC 3+) locally advanced, unresectable, or metastatic solid tumors who have received prior systemic treatment for metastatic or advanced disease and have no satisfactory alternative treatment options in a real-world…

   Stage

   Not phased

   Ages

   18 to 130

   Site

   Research Site, Birmingham, Alabama

   Locations

   18 in total

   Run by

   AstraZeneca

   See if you can join NCT07124000 on ClinicalTrials.gov

8. Study of Oral MRT-2359 With Apalutamide in Prostate Cancer

   This Phase 2, open-label, multicenter study is conducted in patients with castration-resistant prostate cancer. Patients in this study receive MRT-2359, an investigational oral medicine, in combination with apalutamide, an oral medicine used to treat prostate cancer. The main purpose of the study i…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   START Los Angeles, Los Angeles, California

   Locations

   14 in total

   Run by

   Monte Rosa Therapeutics, Inc

   See if you can join NCT07745361 on ClinicalTrials.gov

9. Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer

   The overall aim of the trial is to evaluate the safety, tolerability, and pharmacokinetics (PK) of AMG 509 (monotherapy and in combination with abiraterone acetate and enzalutamide) and to evaluate preliminary efficacy. As of Protocol Amendment 10 (09 July 2025), only Parts 4A expansion, 6, and 7 a…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   City of Hope National Medical Center, Duarte, California

   Locations

   57 in total

   Run by

   Amgen

   See if you can join NCT04221542 on ClinicalTrials.gov

10. A Single-arm, Multicenter Prospective Study to Evaluate the Diagnostic Performance of PROSTest in Men With PSA ≥ 3ng/ml Using Biopsy as the Sole Ground Truth

    This prospective observational study will enroll men referred for prostate biopsy due to elevated PSA and/or abnormal digital rectal examination, with or without pre-biopsy MRI. Peripheral blood will be collected prior to biopsy for PROSTest analysis. Biopsy histopathology will serve as the referen…

    Stage

    Not phased

    Ages

    45 to 80

    Site

    Wren Laboratories, Branford, Connecticut

    Run by

    Wren Laboratories LLC

    See if you can join NCT07454603 on ClinicalTrials.gov

11. A Phase 1b/2a Study of Pocenbrodib as Monotherapy and in Combination With Darolutamide in Participants With mCRPC

    This is a dose-finding study to assess the safety and preliminary antitumor activity of Pocenbrodib alone or with darolutamide in patients with metastatic castration-resistant prostate cancer (mCRPC)

    Stage

    Phase 1

    Ages

    18 and older

    Site

    MemorialCare Orange Coast Medical Center, Fountain Valley, California

    Locations

    19 in total

    Run by

    Pathos AI, Inc.

    See if you can join NCT06785636 on ClinicalTrials.gov

12. Dosing Physical Activity Among Older Cancer Survivors Who Experience Chronic Pain: a Micro-randomized Trial

    The purpose of this study is to assess the best time to deliver a message to increase physical activity and how often participants will experience a pain episode in the 24 hours following their receipt of a message to increase physical activity.

    Stage

    Not phased

    Ages

    65 and older

    Site

    Froedtert Hospital, Milwaukee, Wisconsin

    Run by

    Medical College of Wisconsin

    See if you can join NCT07227077 on ClinicalTrials.gov

13. MRI-based Focal Intraprostatic Simultaneous Integrated Boost (SIB) Intensification With De-escalated Adaptive-risk SBRT for Patients With Low to Intermediate Risk Prostate Cancer

    The goal of this clinical trial is to determine the safety of stereotactic body radiation therapy (SBRT) microboost technique in patients with low to intermediate risk prostate cancer. The main question it aims to answer is: Is microboost SBRT with whole gland de-escalation both safe and effective …

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Lombardi Comprehensive Cancer Center, Georgetown University, Washington D.C., District of Columbia

    Run by

    Georgetown University

    See if you can join NCT07644598 on ClinicalTrials.gov

14. Impact of an Electronic Health Record Maintenance Alert on PSA Screening Rates in a 10-Hospital Integrated Health System

    - The investigators propose a clinical trial to evaluate the impact of annual shared decision making for PSA screening, supported by system-level enhancements to promote evidence-based care: * Defined referral thresholds within the health maintenance reminder, aligned with clinical risk stratificat…

    Stage

    Not phased

    Ages

    40 to 75

    Site

    Washington University School of Medicine, St Louis, Missouri

    Run by

    Washington University School of Medicine

    See if you can join NCT07109427 on ClinicalTrials.gov

15. AI Algorithm-Informed Biopsy for Prostate Cancer Detection With Indeterminate and Low-Risk Prostate MRI Lesions

    Use of AI algorithm for PCa detection is feasible, and AI-informed biopsies (AI-targeted and perilesional biopsy) improves csPCa detection in patients with indeterminate MRI lesions and in patients with low-risk MRI lesions and high-risk clinical features.

    Stage

    Not phased

    Ages

    40 and older

    Site

    University of Arkansas for Medical Sciences, Little Rock, Arkansas

    Run by

    University of Arkansas

    See if you can join NCT07231627 on ClinicalTrials.gov

16. Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate Cancer

    The advent of PSMA-PET has improved sensitivity and specificity in staging prostate cancer, particularly in intermediate- and high-risk disease. This has created uncertainty in the management of patients with PSMA-positive but conventionally negative pelvic lymphadenopathy (i.e., <1 cm in smallest …

    Stage

    Phase 2

    Ages

    30 and older

    Site

    University of Nebraska Medical Center, Omaha, Nebraska

    Run by

    University of Nebraska

    See if you can join NCT07237269 on ClinicalTrials.gov

17. Water Vapor Ablation for Prostate Cancer: Long-Term Registry

    The purpose of the registry is to evaluate real-world safety, efficacy, and patient reported outcomes among participants receiving Vanquish Water Vapor Ablation System therapy (Vanquish Therapy). This includes longitudinal assessment of patients who have received or will receive the therapy one or …

    Stage

    Not phased

    Ages

    Any age

    Site

    WK Advanced Urology Specialists, Bossier City, Louisiana

    Locations

    4 in total

    Run by

    Francis Medical Inc.

    See if you can join NCT07455058 on ClinicalTrials.gov

18. Comparing Acupuncture vs. Sham Acupuncture for the Management of Hot Flashes in Prostate Cancer Patients Receiving Hormone Therapy

    This study is evaluating whether acupuncture may help reduce hot flashes in men receiving hormone therapy for prostate cancer. Hot flashes are a common side effect of androgen deprivation therapy (ADT) and may negatively affect sleep, mood, concentration, daily activities, and overall quality of li…

    Stage

    Not phased

    Ages

    18 to 99

    Site

    University of Kentucky, Lexington, Kentucky

    Run by

    University of Kentucky

    See if you can join NCT07594002 on ClinicalTrials.gov

19. EDRN Prostate MRI Biomarker Study

    The commercialization of MRI fusion biopsies has resulted in a dramatic increase in the use of MRI imaging for prostate cancer. How best to use MRI in the initial prostate biopsy setting given the availability of validated prostate cancer early detection markers is uncertain.This study will allow i…

    Stage

    Not phased

    Ages

    18 and older

    Site

    University of Michigan, Ann Arbor, Michigan

    Run by

    University of Michigan

    See if you can join NCT03784924 on ClinicalTrials.gov

20. FOG-001 in Locally Advanced or Metastatic Solid Tumors

    The goal of this clinical trial is to determine if FOG-001 is safe and effective in participants with locally advanced or metastatic solid tumors or in participants with familial adenomatous polyposis (FAP).

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Mayo Clinic, Phoenix, Arizona

    Locations

    33 in total

    Run by

    Parabilis Medicines, Inc.

    See if you can join NCT05919264 on ClinicalTrials.gov

21. Proof-of-Concept Trial to Assess the Efficacy and Safety of Fezolinetant in Improving Vasomotor Symptoms in Men With Prostate Cancer Undergoing Androgen Deprivation Therapy

    The goal of this clinical trial is to learn if fezolinetant can treat hot flashes (vasomotor symptoms) in men with prostate cancer undergoing androgen deprivation therapy. The main questions it aims to answer are: * Does fezolinetant improve the frequency and severity of hot flashes? * Does fezolin…

    Stage

    Phase 2

    Ages

    40 and older

    Site

    Brigham and Women's Hospital, Boston, Massachusetts

    Run by

    Shehzad Basaria, M.D.

    See if you can join NCT06957691 on ClinicalTrials.gov

22. Genomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate Cancer

    The objective of this study is to see if providing an appropriate therapy based on the genomic testing of prostate tumour tissue will result in an improved clinical response. Each participant will be treated with 8 weeks of a luteinizing hormone-releasing hormone agonist (LHRHa) plus apalutamide (A…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    University of California Davis, Sacramento, California

    Locations

    9 in total

    Run by

    University of British Columbia

    See if you can join NCT04812366 on ClinicalTrials.gov

23. Diagnostic Performance Of Non-Endorectal Coil Multiparametric Magnetic Resonance Imaging Of Prostate With Flexible AIR Coil (DoNEMAC Study)

    Multiparametric MRI (mpMRI) of the prostate is an important tool for diagnosis of clinically significant prostate cancer (csPCa) in men with an elevated serum prostate specific antigen, which can decrease the rate of unnecessary biopsies and reduce the incidence of over-diagnosis of non-csPCa. Furt…

    Stage

    Not phased

    Ages

    18 and older

    Site

    The University of Texas MD Anderson Cancer Center, Houston, Texas

    Run by

    M.D. Anderson Cancer Center

    See if you can join NCT05043012 on ClinicalTrials.gov

24. A Ph Ib Study of REGN5678 Plus Cemiplimab in Patients With mCRPC

    A single-center phase Ib/II dose escalation and dose-expansion clinical trial of REGN5678 plus cemiplimab

    Stage

    Phase 1

    Ages

    18 and older

    Site

    The University of Texas M. D. Anderson Cancer Center, Houston, Texas

    Run by

    M.D. Anderson Cancer Center

    See if you can join NCT06826768 on ClinicalTrials.gov

25. This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.

    This study will explore whether a combination of the investigational drug mevrometostat (PF-06821497) and enzalutamide will work better than taking enzalutamide alone in participants with mCSPC who are ARPI naïve and have not yet received chemotherapy in the mCSPC setting.

    Stage

    Phase 3

    Ages

    18 and older

    Site

    Clearview Cancer Institute (Crestwood), Huntsville, Alabama

    Locations

    337 in total

    Run by

    Pfizer

    See if you can join NCT07028853 on ClinicalTrials.gov